CAR-T cells chimeric antigen receptor T cells

DRUG2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Peking University People's Hospital

Conditions

AMLRefractory/Relapse Acute Myeloid LeukemiaRelapsed/Refractory Acute Myeloid Leukemia(AML)

Phase 1

A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia

Not yet recruitingNCT07441980

Institute of Hematology & Blood Diseases Hospital, ChinaRelapsed/Refractory Acute Myeloid Leukemia(AML)

Start: 2026-03-02End: 2028-06-30Target: 18Updated: 2026-03-02

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

RecruitingNCT07617285

Peking University People's HospitalAML, Refractory/Relapse Acute Myeloid Leukemia

Start: 2026-05-07End: 2029-12-31Target: 27Updated: 2026-06-01